The FDA-approval of the CTLA-4 blocking antibody, ipilimumab (Bristol-Myers Squibb), and the PD-1 blocking antibody, pembrolizumab (Merck) in the treatment of advanced melanoma appear to represent the proverbial tip of the iceberg. The gene discussed is CTLA4; the disease is melanoma.